Quantitation of slow release triptorelin in beagle dog plasma by liquid chromatography-tandem mass spectrometry

Journal of Pharmaceutical and Biomedical Analysis

Volumn 66, Issue , 2012, Pages 334-338

  Han, Jiangbin ^a   Sun, Jiye ^a   Sha, Chunjie ^a   Zhang, Jinfeng ^b   Gai, Yunyun ^a   Li, Youxin ^a   Liu, Wanhui ^a,b  

^a State Key Laboratory of Long acting and Targeting Drug Delivery System   (China)

^b YANTAI UNIVERSITY   (China)

Author keywords

LC MS MS; Pharmacokinetics; Plasma; Quantitation; Triptorelin

Indexed keywords

FORMIC ACID; NITROGEN; OCTREOTIDE; TRIPTORELIN; WATER;

ACCURACY; ANIMAL EXPERIMENT; ARTICLE; CHEMICAL REACTION; CONTROLLED STUDY; DOG; DRUG FORMULATION; DRUG STABILITY; ELUTION; EVAPORATION; LIMIT OF QUANTITATION; LIQUID CHROMATOGRAPHY; MALE; NONHUMAN; PRIORITY JOURNAL; SLOW DRUG RELEASE; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; VALIDATION PROCESS;

ANIMALS; ANTINEOPLASTIC AGENTS, HORMONAL; CALIBRATION; CHROMATOGRAPHY, LIQUID; DELAYED-ACTION PREPARATIONS; DOGS; INJECTIONS, INTRAMUSCULAR; LIMIT OF DETECTION; MALE; REPRODUCIBILITY OF RESULTS; SENSITIVITY AND SPECIFICITY; SOLID PHASE EXTRACTION; TANDEM MASS SPECTROMETRY; TRIPTORELIN PAMOATE;

EID: 84862827294     PISSN: 07317085     EISSN: 1873264X     Source Type: Journal    
DOI: 10.1016/j.jpba.2012.02.021     Document Type: Article

References (11)

1. Redding T.W., Schally G. Inhibition of prostate tumor growth in two rats models by chronic administration of D-Trp-6 analogue of luteinizing hormone-releasing hormone. Proc. Natl. Acad. Sci. U.S.A. 1981, 78:6509-6512.
2. Miller W.R., Scott W.N., Morris R., Fraser M.M., Sharpe R.M. Growth of human breast cancer cells inhibited by a luteinizing hormone-releasing hormone agonist. Nature 1985, 313:231-233.
3. Labile F., Belanger A., Dupont A., Edmond K., Lacoursiere Y., Monfette G. Combined treatment with LHRH agonist and pure antiandrogen in advanced carcinoma of prostate. Lancet 1984, 84:1090.
4. Corbin A. From contraception to cancer: a review of the therapeutic applications of LHRH analogues as antitumor agents. Yale J. Biol. Med. 1982, 55:27-47.
5. Redding T.W., Kastin A.J., Gonzales-Barcena D. The half-life, metabolismand excretion of titrated luteinizing hormone-releasing hormone (LH-RH) in man. J Clin. Endocrinol. Metab. 1973, 37:626-631.
6. Schally A.V., Coy D.H., Arimura A. LHRH agonists and antagonists. Int. Gynaecol. Obstet. 1980, 18:318-324.
7. Schally A.V., Comaru-SchaUy A.M., Redding T.W. Antitumor effects of analogs of hypothalamic hormones in endocilne-dependent cancers. Proc. Soc. Exp. Biol. Med. 1984, 175:259-281.
8. Villavicencio H., Rubio B.J., Regalado R., Chéchile G., Palou J., Algaba F. Grade, local stage and growth pattern as prognostic factors in carcinoma of the penis. Eur. Urol. 1997, 32:442-447.
9. Eric E., Katy D., Maryvonne C., Catherine R., Fernand D. Radioimmunoassay of [D-Trp6]-luteinizing hormone-releasing hormone: its application to animal pharmacokinetic studies after single injection and long-acting formulation administration. Regul. Pept. 1986, 14:155-167.
10. Guidance for Industry Bioanalytical Method Validation, U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CEDR), Center for Veterinary Medicine (CVM), BP, May 2001. http://www.fda.gov/cder/guidance/4252fnl.htm.
11. Niessen W.M.A., Manini P., Andreoli R. Matrix effects in quantitative pesticide analysis using liquid chromatography-mass spectrometry. Mass Spectrom. Rev. 2006, 25:881-899.